» Articles » PMID: 16936212

Persistent Renal Hypertrophy and Faster Decline of Glomerular Filtration Rate Precede the Development of Microalbuminuria in Type 1 Diabetes

Overview
Journal Diabetes
Specialty Endocrinology
Date 2006 Aug 29
PMID 16936212
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

Soon after the onset of type 1 diabetes, renal hypertrophy and hyperfiltration become manifest, particularly among patients who will subsequently develop diabetic nephropathy. Whether these early renal dysfunctions are involved in the pathogenesis of diabetic nephropathy is currently unclear. We evaluated, during the same day, kidney volume and glomerular filtration rate (GFR) in 146 patients with type 1 diabetes and normal renal function. All the individuals were then monitored for a mean of 9.5 +/- 4.4 years for the development of microalbuminuria. Kidney volume and GFR were reevaluated in a subset of 68 patients 4 years after baseline. During follow-up, microalbuminuria developed in 27 of 146 diabetic patients. At baseline, kidney volume (312.8 +/- 52.6 vs. 281.4 +/- 46.1 vs. 236.8 +/- 41.6 ml/1.73 m(2), P < 0.05) but not GFR was increased in patients predisposed to microalbuminuria. Risk of progression was higher in patients with increased kidney volume (P = 0.0058). Patients predisposed to microalbuminuria showed a stable increase in kidney volume (P = 0.003), along with a faster decline of GFR (P = 0.01). Persistent renal hypertrophy and faster decline of GFR precede the development of microalbuminuria in type 1 diabetes. These findings support the hypothesis that renal hypertrophy precedes hyperfiltration during the development of diabetic nephropathy.

Citing Articles

SGLT2 Inhibitors: The First Endothelial-Protector for Diabetic Nephropathy.

Viggiano D, Joshi R, Borriello G, Cacciola G, Gonnella A, Gigliotti A J Clin Med. 2025; 14(4).

PMID: 40004772 PMC: 11856817. DOI: 10.3390/jcm14041241.


Effects of semaglutide, empagliflozin and their combination on renal diffusion-weighted MRI and total kidney volume in patients with type 2 diabetes: a post hoc analysis from a 32 week randomised trial.

Vernstrom L, Gullaksen S, Sorensen S, Ringgaard S, Laustsen C, Birn H Diabetologia. 2024; 67(10):2175-2187.

PMID: 39078489 PMC: 11447057. DOI: 10.1007/s00125-024-06228-y.


The Role of Selenium Nanoparticles in Addressing Diabetic Complications: A Comprehensive Study.

Satpathy S, Panigrahi L, Arakha M Curr Top Med Chem. 2024; 24(15):1327-1342.

PMID: 38561614 DOI: 10.2174/0115680266299494240326083936.


Mechanisms of Diabetic Nephropathy Not Mediated by Hyperglycemia.

Viggiano D J Clin Med. 2023; 12(21).

PMID: 37959313 PMC: 10650633. DOI: 10.3390/jcm12216848.


Therapeutic potential of a novel peripherally restricted CB1R inverse agonist on the progression of diabetic nephropathy.

Jacquot L, Pointeau O, Roger-Villeboeuf C, Passilly-Degrace P, Belkaid R, Regazzoni I Front Nephrol. 2023; 3:1138416.

PMID: 37675364 PMC: 10479578. DOI: 10.3389/fneph.2023.1138416.